Core Viewpoint - Soligenix, Inc. has successfully closed a public offering, raising approximately $7.5 million, which extends its cash runway through the end of 2026 to support key development milestones in its biopharmaceutical projects [1][3]. Funding and Financial Details - The company sold 5,555,560 shares of common stock and warrants at a combined price of $1.35 per share [1]. - The warrants have an exercise price of $1.35 per share, are immediately exercisable, and will expire five years from the issuance date [1]. - The net proceeds from the offering will be allocated to research and development, commercialization activities, working capital, and general corporate purposes [3]. Existing Warrants Amendment - Certain existing warrants from May 2023, April 2024, and July 2024 will be amended to have a reduced exercise price of $1.35 per share, aligning their expiration with the new warrants sold in the offering [2]. Company Overview - Soligenix is a late-stage biopharmaceutical company focused on developing treatments for rare diseases with unmet medical needs [6]. - The company is advancing its Specialized BioTherapeutics segment, particularly HyBryte™ (SGX301), aimed at treating cutaneous T-cell lymphoma, and is seeking regulatory approvals following successful Phase 3 study results [6]. - The Public Health Solutions segment includes vaccine development programs for ricin toxin, filoviruses, and COVID-19, supported by government funding [7].

Core Viewpoint - Contango ORE, Inc. has successfully completed a public offering of common shares, raising approximately $50 million to fund its mining projects and general corporate purposes [1][2]. Group 1: Offering Details - The offering consisted of 1,975,000 common shares priced at $20.00 each and included a pre-funded warrant for 525,000 shares at $19.99 each, resulting in gross proceeds of around $50 million before expenses [1]. - Canaccord Genuity acted as the Sole Bookrunner, with Cormark Securities as Lead Manager and other firms as Co-Managers for the offering [3]. Group 2: Use of Proceeds - The net proceeds will be allocated to advance the Lucky Shot project towards a mine production decision within two years, involving drilling and underground development [2]. - Funds will also support the Johnson Tract project, including road construction, camp winterization, exploration tunnel construction, and feasibility planning, pending necessary permits [2]. Group 3: Company Overview - Contango is engaged in gold exploration in Alaska, holding a 30% interest in the Peak Gold project and leases on the Johnson Tract and Lucky Shot projects, along with ownership of additional mining claims [5].

Core Viewpoint - Transocean Ltd. is conducting a public offering of 125 million shares at a price of $3.05 per share, raising approximately $381.25 million in gross proceeds before expenses [1][3]. Group 1: Offering Details - The offering has increased from an initial proposal of 100 million shares to 125 million shares [1]. - Transocean has granted underwriters a 30-day option to purchase an additional 18.75 million shares at the public offering price [1]. - The offering is expected to close on September 26, 2025, pending customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be used primarily for the repayment or redemption of indebtedness, specifically a portion of the $655 million in 8.00% Senior Notes due February 2027 [3]. - Any remaining proceeds not used for debt repayment will be allocated for general corporate purposes [3]. Group 3: Underwriters - Citigroup and Morgan Stanley are serving as joint book-running managers for the offering [2]. - DNB Carnegie, Goldman Sachs & Co. LLC, and Wells Fargo Securities are also acting as joint book-running managers [2]. - SB1 Markets is participating as a co-manager for the offering [2]. Group 4: Company Overview - Transocean is a leading provider of offshore contract drilling services, focusing on ultra-deepwater and harsh environment drilling [6]. - The company operates a fleet of 27 mobile offshore drilling units, including 20 ultra-deepwater floaters and seven harsh environment floaters [7].

Company Overview - MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel precision peptide therapies for endocrine and metabolic disorders [5] - The company utilizes its proprietary PEP™ platform to advance a pipeline of candidates targeting significant unmet medical needs with large market opportunities [5] Public Offering Details - MBX Biosciences announced the pricing of its upsized public offering of 11,108,055 shares at a price of $18.00 per share, expecting gross proceeds of approximately $199.9 million before deductions [1] - The offering includes a 30-day option for underwriters to purchase an additional 1,666,208 shares at the public offering price [1] - The offering is expected to close on September 26, 2025, pending customary closing conditions [1] Underwriters - J.P. Morgan, Jefferies, TD Cowen, and Guggenheim Securities are acting as joint book-running managers for the offering [2] - Citizens Capital Markets and Oppenheimer & Co. are serving as co-lead managers [2] Regulatory Compliance - A registration statement for the offering was filed with the Securities and Exchange Commission and declared effective on September 24, 2025 [3] - The offering is being conducted solely through a prospectus [3]

Core Viewpoint - Transocean Ltd. plans to offer and sell 100,000,000 shares in an underwritten public offering, with an additional option for underwriters to purchase up to 15,000,000 shares [1][2]. Group 1: Offering Details - The shares are being offered at a par value of $0.10, and the offering is part of a shelf registration statement filed with the SEC [1][4]. - Citigroup and Morgan Stanley are acting as joint book-running managers for the offering [2]. - The net proceeds from the offering will primarily be used for the repayment of a portion of the $655 million aggregate principal amount of the 8.00% Senior Notes due February 2027 [3]. Group 2: Company Overview - Transocean is a leading international provider of offshore contract drilling services, focusing on ultra-deepwater and harsh environment drilling [6]. - The company operates a fleet of 27 mobile offshore drilling units, including 20 ultra-deepwater floaters and seven harsh environment floaters [7].

Core Viewpoint - Aeluma, Inc. plans to conduct an underwritten public offering of its common stock, with a potential additional 15% of shares available for purchase by the underwriter [1][2]. Group 1: Offering Details - The offering is subject to market conditions and there is no assurance regarding its completion or the final terms [1]. - Craig-Hallum is the sole book-running manager for the offering [2]. - Aeluma will file a preliminary prospectus supplement with the SEC detailing the terms of the offering [4]. Group 2: Use of Proceeds - The net proceeds from the offering are intended for business development, advancing manufacturing processes, and general working capital [2]. Group 3: Company Overview - Aeluma specializes in high-performance photonic and electronic technologies, combining compound semiconductors with scalable manufacturing for mass market microelectronics [5]. - The company's technology has applications in various sectors including mobile, AI, defense, aerospace, robotics, automotive, AR/VR, and quantum [5]. - Aeluma is headquartered in Goleta, California, and operates advanced R&D and manufacturing capabilities for semiconductor production [5].

Group 1 - Robin Energy Ltd. announced the closing of its underwritten public offering of 5,769,230 shares at a price of $1.30 per share, raising approximately $8.6 million in gross proceeds [1][2] - The underwriter, Maxim Group LLC, partially exercised its overallotment option, purchasing an additional 864,770 shares for about $1.1 million in gross proceeds [1][2] - The net proceeds from the offering will be used for working capital and general corporate purposes [2] Group 2 - The offering was conducted under an effective shelf registration statement filed with the SEC on April 24, 2025, and declared effective on April 28, 2025 [3] - A final prospectus supplement and accompanying prospectus have been filed with the SEC and are available on their website [3] Group 3 - Robin Energy is an international ship-owning company that provides energy transportation services globally, owning one Handysize tanker and one LPG carrier [5]

Group 1 - Robin Energy Ltd. announced a public offering of 5,769,230 shares at a price of $1.30 per share, expecting gross proceeds of approximately $7.5 million before expenses [1][2] - The offering is set to close on or about September 12, 2025, subject to customary closing conditions [1] - Maxim Group LLC is the sole book-running manager for the offering, and the net proceeds will be used for working capital and general corporate purposes [2] Group 2 - The offering is made under an effective shelf registration statement filed with the SEC on April 24, 2025, and declared effective on April 28, 2025 [3] - A preliminary prospectus supplement and accompanying prospectus have been filed with the SEC and are available on their website [3] Group 3 - Robin Energy is an international ship-owning company that provides energy transportation services globally, owning one Handysize tanker and one LPG carrier [5]

Company Overview - Robin Energy Ltd. is an international ship-owning company that provides energy transportation services globally, owning one Handysize tanker vessel and one LPG carrier for transporting petrochemical gases and refined petroleum products [5]. Offering Details - The company has commenced a public offering of shares of its common stock or pre-funded warrants, with all shares to be sold by Robin Energy [1]. - Maxim Group LLC is acting as the sole book-running manager for the offering [2]. - The net proceeds from the offering are intended for working capital and general corporate purposes [2]. - The offering is made pursuant to an effective shelf registration statement on Form F-3, previously filed with the U.S. Securities and Exchange Commission (SEC) [3]. Regulatory Information - A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and will be available on the SEC's website [3]. - The press release does not constitute an offer to sell or solicitation of an offer to buy these securities in any jurisdiction where such offer would be unlawful [4].

Core Viewpoint - Veritone, Inc. announced a proposed underwritten public offering of shares of its common stock, intending to use the net proceeds for working capital and general corporate purposes, including debt service and repayment of indebtedness [1] Group 1 - The company is a leader in building human-centered enterprise AI solutions [1] - The offering is subject to market and other conditions, with no assurance of completion [1]